Global Information
회사소개 | 문의 | 비교리스트

만성신장질환에 의한 빈혈 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035

리서치사 Datamonitor Healthcare
발행일 2018년 07월 상품 코드 365170
페이지 정보 영문 318 Pages
가격
US $ 22,000 ₩ 25,999,000 PDF by E-mail (Single User License)
US $ 107,800 ₩ 127,398,000 PDF by E-mail (Global License)


만성신장질환에 의한 빈혈 : 역학 및 환자 기반 시장 예측, 치료 알고리즘, 출시 및 개발중인 약제 분석 Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035
발행일 : 2018년 07월 페이지 정보 : 영문 318 Pages

새로운 HIF 저해제 Roxadustat의 투입에 의해 바이오시밀러에 의한 Epogen 침식이 상쇄되어 시장 성장이 촉진될 전망입니다.

만성신장질환에 의한 빈혈(Anemia In Chronic Kidney Disease) 치료제 동향에 대해 조사했으며, 시장의 정의와 개요, 질환의 정의와 진단, 현재 치료 옵션, 처방 동향, 미충족 요구, 주요 출시된 제품의 프로파일, 파이프라인 동향 등의 정보를 전해드립니다.

1. 예측 : 만성신장질환에 의한 빈혈

  • 주요 요약
  • 시장 개요와 동향
  • 시장 정의와 조사 방법
  • Aranesp(darbepoetin alfa)
  • Auryxia(ferric citrate)
  • DexFerrum(iron dextran)
  • Epogen(epoetin alfa)
  • Feraccru(ferric trimaltol)
  • Feraheme(ferumoxytol)
  • Injectafer(ferric carboxymaltose)
  • Mircera(methoxy polyethylene glycol-epoetin beta)
  • NeoRecormon(epoetin beta)
  • Roxadustat
  • Venofer(iron sucrose)
  • 1차 조사 방법

2. 치료 : 만성신장질환에 의한 빈혈

  • 주요 요약
  • 1차 조사 방법
  • 질환의 정의와 진단
  • 환자 세분화
  • 국가별 치료 트리
  • 현재 치료 옵션
  • 처방 동향
  • 미충족 요구
  • 향후 치료법

3. 역학 : 만성신장질환에 의한 빈혈

  • 주요 요약
  • 정보 출처와 조사 방법
  • 예측
  • 역학자의 분석
  • 강점과 제약

4. 출시된 약제 : 만성신장질환에 의한 빈혈

  • 주요 요약
  • 제품 개요
  • 제품 프로파일 : Aranesp
  • 제품 프로파일 : Epogen
  • 제품 프로파일 : Mircera
  • 제품 프로파일 : Triferic
  • 제품 프로파일 : Venofer

5. 파이프라인 : 만성신장질환에 의한 빈혈

  • 주요 요약
  • 임상 파이프라인 개요
  • 제품 프로파일(후기 단계) : Auryxia
  • 제품 프로파일(후기 단계) : Feraccru
  • 제품 프로파일(후기 단계) : roxadustat
KSM 16.08.19

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Overview

Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Market Snapshot

  • The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
  • Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
  • By 2037, there will be an estimated 28% increase in total prevalent cases in the US, Japan, and five major EU markets.
  • Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
  • Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.

TABLE OF CONTENTS

FORECAST: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • PRODUCT PROFILE: ARANESP
  • PRODUCT PROFILE: AURYXIA
  • PRODUCT PROFILE: DEXFERRUM
  • PRODUCT PROFILE: EPOGEN
  • PRODUCT PROFILE (LATE STAGE): FERACCRU
  • PRODUCT PROFILE: FERAHEME
  • PRODUCT PROFILE: INJECTAFER
  • PRODUCT PROFILE: MIRCERA
  • PRODUCT PROFILE: NEORECORMON
  • PRODUCT PROFILE: VENOFER
  • PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

TREATMENT: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 09 March 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • COUNTRY TREATMENT TREES
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN ANEMIA IN CHRONIC KIDNEY DISEASE
  • FUTURE TREATMENT

EPIDEMIOLOGY: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 17 July 2018)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY

MARKETED DRUGS: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ARANESP
  • PRODUCT PROFILE: AURYXIA
  • PRODUCT PROFILE: DEXFERRUM
  • PRODUCT PROFILE: EPOGEN
  • PRODUCT PROFILE: FERAHEME
  • PRODUCT PROFILE: INJECTAFER
  • PRODUCT PROFILE: MIRCERA
  • PRODUCT PROFILE: NEORECORMON
  • PRODUCT PROFILE: VENOFER

PIPELINE: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): FERACCRU
  • PRODUCT PROFILE (LATE STAGE): ROXADUSTAT

LIST OF FIGURES

  • Figure 1: Anemia in chronic kidney disease - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for anemia in chronic kidney disease
  • Figure 3: Anemia in chronic kidney disease market sales across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 4: Sales of ESAs and roxadustat in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 5: Anemia in chronic kidney disease market sales in the US, Japan, and five major EU markets, by class, 2015-24
  • Figure 6: Sales of Epogen and biosimilar epoetin alfa in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 7: Sales of biosimilar epoetin alfa in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 8: Sales of iron supplements in anemia in chronic kidney disease in the US, Japan, and five major EU markets, by drug, 2015-24
  • Figure 9: Patient-based forecast methodology for anemia in chronic kidney disease
  • Figure 10: Price sources and calculations, by country
  • Figure 11: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • Figure 12: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 14: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • Figure 16: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 18: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • Figure 20: Epogen for anemia in chronic kidney disease - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 23: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 24: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 27: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 28: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 29: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 32: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • Figure 33: Mircera for anemia in chronic kidney disease - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 36: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 37: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • Figure 38: Venofer for anemia in chronic kidney disease - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 41: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 42: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • Figure 43: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 44: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 45: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 46: Physician-estimated rate of diagnosis of anemia in chronic kidney disease, by country (%)
  • Figure 47: Proportion of anemia in chronic kidney disease patients at each grade of disease, by country (%)
  • Figure 48: Proportion of patients with anemia in chronic kidney disease receiving treatment from each physician type, by country (%)
  • Figure 49: Proportion of patients with mild anemia receiving each treatment type, by country (%)
  • Figure 50: Proportion of patients with moderate anemia receiving each treatment type, by country (%)
  • Figure 51: Proportion of patients with severe anemia receiving each treatment type, by country (%)
  • Figure 52: Proportion of patients with very severe anemia receiving each treatment type, by country (%)
  • Figure 53: Proportion of patients prescribed top five pharmacological treatments, by country (%)
  • Figure 54: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each ESA (alone or in combination), by country
  • Figure 55: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each iron supplement (alone or in combination), by country
  • Figure 56: Average length of iron supplement treatment, by anemia grade (days)
  • Figure 57: Expected epoetin alfa biosimilar use in new patients compared to physician-reported use in the 5EU and Japan, by country (%)
  • Figure 58: Expected epoetin alfa biosimilar use in patients currently receiving epoetin alfa compared to physician-reported use in the 5EU and Japan, by country (%)
  • Figure 59: Newly diagnosed patients expected to be prescribed an oral ESA, one and three years post-launch, by country (%)
  • Figure 60: Patients on stable ESA therapy expected to be switched to an oral ESA, one and three years post-launch, by country (%)
  • Figure 61: Trends in total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017-37
  • Figure 62: Aranesp for anemia in chronic kidney disease - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Aranesp for anemia in chronic kidney disease
  • Figure 65: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 66: Auryxia for anemia in chronic kidney disease - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Auryxia for anemia in chronic kidney disease
  • Figure 69: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 70: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015-24
  • Figure 71: Epogen for anemia in chronic kidney disease - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 73: Datamonitor Healthcare's drug assessment summary of Epogen for anemia in chronic kidney disease
  • Figure 74: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 75: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015-24
  • Figure 76: Injectafer for anemia in chronic kidney disease - SWOT analysis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 78: Datamonitor Healthcare's drug assessment summary of Injectafer for anemia in chronic kidney disease
  • Figure 79: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
  • Figure 80: Mircera for anemia in chronic kidney disease - SWOT analysis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 82: Datamonitor Healthcare's drug assessment summary of Mircera for anemia in chronic kidney disease
  • Figure 83: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

LIST OF TABLES

  • Figure 84: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015-24
  • Figure 85: Venofer for anemia in chronic kidney disease - SWOT analysis
  • Figure 86: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 87: Datamonitor Healthcare's drug assessment summary of Venofer for anemia in chronic kidney disease
  • Figure 88: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 89: Feraccru for anemia in chronic kidney disease - SWOT analysis
  • Figure 90: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 91: Datamonitor Healthcare's drug assessment summary of Feraccru for anemia in chronic kidney disease
  • Figure 92: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 93: Roxadustat for anemia in chronic kidney disease - SWOT analysis
  • Figure 94: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 95: Datamonitor Healthcare's drug assessment summary of roxadustat for anemia in chronic kidney disease
  • Figure 96: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24
  • Table 1: Summary of drug classes and molecules included in Datamonitor Healthcare's anemia in chronic kidney disease patient-based forecast
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Hematologists and nephrologists surveyed for the anemia in chronic kidney disease primary research study, 2015
  • Table 4: Aranesp drug profile
  • Table 5: Aranesp pivotal trial data in anemia in chronic kidney disease
  • Table 6: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • Table 7: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 8: Auryxia drug profile
  • Table 9: Auryxia Phase III data in anemia in chronic kidney disease
  • Table 10: Auryxia Phase II data in anemia in chronic kidney disease
  • Table 11: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 12: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • Table 13: Epogen drug profile
  • Table 14: Epogen pivotal trial data in anemia in chronic kidney disease
  • Table 15: Epogen other late-phase trial data in anemia in chronic kidney disease
  • Table 16: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 17: Feraccru drug profile
  • Table 18: Feraccru Phase III trials in anemia in chronic kidney disease
  • Table 19: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 20: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 21: Injectafer drug profile
  • Table 22: Injectafer Phase III data in anemia in chronic kidney disease
  • Table 23: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • Table 24: Mircera drug profile
  • Table 25: Mircera pivotal trial data in anemia in chronic kidney disease
  • Table 26: Mircera late-phase trial data in anemia in chronic kidney disease
  • Table 27: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 28: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • Table 29: Venofer drug profile
  • Table 30: Venofer pivotal trial data in anemia in chronic kidney disease
  • Table 31: Venofer late-phase trial data in anemia in chronic kidney disease
  • Table 32: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 33: Roxadustat drug profile
  • Table 34: Roxadustat Phase III trials in anemia in chronic kidney disease
  • Table 35: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • Table 36: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 37: Nephrologists and hematologists surveyed for the anemia in chronic kidney disease primary research study, November 2015
  • Table 38: Grades of anemia in chronic kidney disease and corresponding hemoglobin levels
  • Table 39: Treatments available for anemia in chronic kidney disease across the US, Japan, and five major EU markets
  • Table 40: Definitions applied for anemia case ascertainment
  • Table 41: Definition applied for CKD case ascertainment and severity segmentation
  • Table 42: Sources used for the epidemiological analysis of anemia in CKD in the US, Japan, and five major EU markets, by country
  • Table 43: Total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017-37
  • Table 44: Key marketed drugs for anemia in chronic kidney disease
  • Table 45: Aranesp drug profile
  • Table 46: Aranesp pivotal trial data in anemia in chronic kidney disease
  • Table 47: Aranesp other late-phase trial data in anemia in chronic kidney disease
  • Table 48: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 49: Auryxia drug profile
  • Table 50: Auryxia Phase III data in anemia in chronic kidney disease
  • Table 51: Auryxia Phase II data in anemia in chronic kidney disease
  • Table 52: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 53: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015-24
  • Table 54: Epogen drug profile
  • Table 55: Epogen pivotal trial data in anemia in chronic kidney disease
  • Table 56: Epogen other late-phase trial data in anemia in chronic kidney disease
  • Table 57: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 58: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015-24
  • Table 59: Injectafer drug profile
  • Table 60: Injectafer Phase III data in anemia in chronic kidney disease
  • Table 61: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
  • Table 62: Mircera drug profile
  • Table 63: Mircera pivotal trial data in anemia in chronic kidney disease
  • Table 64: Mircera late-phase trial data in anemia in chronic kidney disease
  • Table 65: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 66: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015-24
  • Table 67: Venofer drug profile
  • Table 68: Venofer pivotal trial data in anemia in chronic kidney disease
  • Table 69: Venofer late-phase trial data in anemia in chronic kidney disease
  • Table 70: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 71: Phase III pipeline products in development for anemia in chronic kidney disease
  • Table 72: Feraccru drug profile
  • Table 73: Feraccru Phase III trials in anemia in chronic kidney disease
  • Table 74: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 75: Roxadustat drug profile
  • Table 76: Roxadustat Phase III trials in anemia in chronic kidney disease
  • Table 77: Roxadustat Phase II and III data in anemia in chronic kidney disease
  • Table 78: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24
Back to Top
전화 문의
F A Q